Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol ATI001-102 Expansion Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma

Trial Profile

Protocol ATI001-102 Expansion Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 11 Feb 2019 According to a ZIOPHARM Oncology media release, preliminary data are anticipated at medical meetings this year.
    • 11 Feb 2019 According to a ZIOPHARM Oncology media release, a total of 36 patients have been treated in less than six months. A majority of the newly enrolled patients in the substudy were treated with low-dose steroids.
    • 11 Feb 2019 Status changed from recruiting to active, no longer recruiting, according to a ZIOPHARM Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top